CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.
CanSino Biologics Inc. has reported a significant increase in its total revenue for the year ending December 31, 2024, with a 137.01% rise compared to the previous year, reaching approximately RMB846.34 million. Despite this revenue growth, the company still faced a net loss of approximately RMB378.88 million, although this represents a substantial reduction of 74.45% from the previous year. The company’s total assets decreased by 14.60%, and equity attributable to shareholders fell by 6.91%. These financial results highlight a challenging yet improving financial position for CanSino Biologics, with implications for its stakeholders as it navigates the competitive biopharmaceutical landscape.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, primarily focusing on the development, production, and commercialization of innovative vaccines for infectious diseases. The company operates in the biopharmaceutical industry and has been involved in the production of COVID-19 vaccines.
YTD Price Performance: 29.52%
Average Trading Volume: 1,172,433
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$12.22B
Learn more about 6185 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com